You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Patent: 10,253,102

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,253,102

Title:	Antigen-binding proteins that activate the leptin receptor
Abstract:	The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
Inventor(s):	Gromada; Jesper (Scarsdale, NY), Stevis; Panayiotis (West Orange, NJ), Altarejos; Judith (Chappaqua, NY)
Assignee:	REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)
Application Number:	16/007,848
Patent Claims:	see list of patent claims

Details for Patent 10,253,102

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014	⤷ Try a Trial	2035-10-12
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/18/2014	⤷ Try a Trial	2035-10-12
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	09/04/2020	⤷ Try a Trial	2035-10-12
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	08/27/2015	⤷ Try a Trial	2035-10-12
Amgen, Inc.	REPATHA	evolocumab	Injection	125522	07/08/2016	⤷ Try a Trial	2035-10-12
Regeneron Pharmaceuticals, Inc.	PRALUENT	alirocumab	Injection	125559	07/24/2015	⤷ Try a Trial	2035-10-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.